Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm

The American Journal of Cardiology
B N Singh

Abstract

Numerous developments in our knowledge of arrhythmias during the past decade or so have had a major influence on antiarrhythmic drug therapy. It has become increasingly evident that arrhythmias merit treatment not only for the relief of symptoms, with improvement in quality of life, but also for the prolongation of survival by decreasing arrhythmic deaths. No longer can mere suppression of arrhythmias, symptomatic or asymptomatic, be equated with prolonged survival. We now know that antiarrhythmic drugs that act by blocking sodium channels can increase mortality and that the most important determinants of arrhythmia mortality are the degree and nature of ventricular dysfunction. To these considerations must be added the advances in nonpharmacologic approaches to controlling cardiac arrhythmias. There has been a shift to the use of implantable devices and of drugs with alternative modes of action, such as beta blockers and class III drugs (e.g., sotalol, amiodarone). However, the side-effect profiles of these 2 classes of compounds have led to the synthesis and characterization of agents that act simply by blocking > or = 1 membrane ion channels. The isolated block of the rapid component of the delayed rectifier potassium curren...Continue Reading

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators
Oct 15, 1991·The American Journal of Cardiology·A P HallstromC E Fahrenbruch
Mar 1, 1974·American Heart Journal·B N Singh, O Hauswirth
Jan 1, 1994·Current Opinion in Cardiology·B N Singh, R Ahmed
Jul 1, 1997·Cardiovascular Research·I KodamaJ Toyama
Dec 12, 1997·Journal of Cardiovascular Electrophysiology·S SicouriC Antzelevitch

❮ Previous
Next ❯

Citations

Jun 19, 2001·Current Cardiology Reports·B N Singh, J S Sarma
Sep 25, 2002·Clinical Cardiology·Mithilesh Kumar DasMajesh Makan
Aug 3, 2010·Heart and Vessels·Harumichi NakagawaItsuo Kodama
Nov 10, 2007·European Journal of Pharmacology·Rong-qian ShiItsuo Kodama
Nov 30, 2006·Annals of the New York Academy of Sciences·Max J Lab
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Abrol, R L Page
Jul 11, 2000·Japanese Journal of Pharmacology·J Tamargo
Mar 31, 1999·The Veterinary Clinics of North America. Small Animal Practice·K N Strickland
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S Doshi, B N Singh
Jan 24, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh
Mar 22, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·B N Singh
Jul 14, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·B N Singh, J S Sarma
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·B N Singh, S Doshi
Jun 21, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Gerald V Naccarelli
May 15, 2003·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh
May 15, 2003·Journal of Cardiovascular Pharmacology and Therapeutics·Paul Dorian
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh, Nitin Wadhani
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S K Doshi, B N Singh
Feb 3, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Cheng-Cheng YangJian-Ping Cai
Aug 2, 2003·Nursing Management·Linda Josephson, Maureen McMullen
Jan 28, 2003·Journal of Cardiovascular Pharmacology·Patrick GautierDino Nisato
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·B N Singh
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·P P SharmaB N Singh
Aug 3, 2001·Cardiovascular Drug Reviews·J ChengI Kodama
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·M Valderrábano, B N Singh
Oct 3, 2002·Dimensions of Critical Care Nursing : DCCN·Linda Josephson, Maureen McMullen
Jan 19, 2011·Fundamental & Clinical Pharmacology·Paolo Emilio PudduJoffrey Ducroq
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·B N Singh
Oct 12, 2018·Gynecologic Oncology·Anil Belur NagarajAnalisa DiFeo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.